Does Auris Medical Holding AG (EARS) Have Any Gas After Reaching Yearly Low?

March 14, 2018 - By Michael Collier

The stock of Auris Medical Holding AG (NASDAQ:EARS) hit a new 52-week low and has $1.49 target or 3.00 % below today’s $1.54 share price. The 5 months bearish chart indicates high risk for the $93.90M company. The 1-year low was reported on Mar, 14 by If the $1.49 price target is reached, the company will be worth $2.82M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 39.09% or $0.985 during the last trading session, reaching $1.535. About 733,767 shares traded. Auris Medical Holding AG (NASDAQ:EARS) has declined 79.78% since March 14, 2017 and is downtrending. It has underperformed by 96.48% the S&P500.

Auris Medical Holding AG (NASDAQ:EARS) Ratings Coverage

Among 3 analysts covering Auris Medical Holding AG (NASDAQ:EARS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Auris Medical Holding AG had 4 analyst reports since March 15, 2016 according to SRatingsIntel. The stock has “Buy” rating by Roth Capital on Friday, June 30. The stock has “Buy” rating by Needham on Friday, August 19. As per Tuesday, March 15, the company rating was maintained by Jefferies.

More recent Auris Medical Holding AG (NASDAQ:EARS) news were published by: which released: “Auris Medical Provides Business Update” on March 13, 2018. Also published the news titled: “Idera Pharmaceuticals, Inc. (IDRA) and Auris Medical Holding AG (EARS …” on March 06, 2018.‘s news article titled: “Auris Medical to Host Key Opinion Leader Call Focused on Keyzilen® Tinnitus …” with publication date: February 26, 2018 was also an interesting one.

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. The company has market cap of $93.90 million. The Company’s product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. It currently has negative earnings. The firm is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.